Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: A prospective, parallel-group, randomized, controlled study with 36-month follow-up

American Journal of Hematology

Volumn 85, Issue 11, 2010, Pages 894-896

  Georgakopoulos, Peter ^a   Roussou, Paraskevi ^a   Matsakas, Evangellos ^b   Karavidas, Apostolos ^b   Anagnostopoulos, Nick ^b   Marinakis, Theodoros ^b   Galanopoulos, Athanasios ^b   Georgiakodis, Fotis ^c   Zimeras, Stelios ^d   Kyriakidis, Michael ^a   Ahimastos, Apostolos ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

^b KAT HOSPITAL   (Greece)

^c Cardiology Department of Gennimatas General Hospital of Athens ^*  (Greece)

^d UNIVERSITY OF THE AEGEAN   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ENALAPRIL; METOPROLOL; PREDNISOLONE; RITUXIMAB; VINBLASTINE; VINCRISTINE;

ADULT; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GROUPS BY AGE; HEART FAILURE; HEART PROTECTION; HODGKIN DISEASE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; OPEN STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTONIC AGENTS; CHEMOPREVENTION; DOXORUBICIN; ENALAPRIL; FEMALE; HEART DISEASES; HUMANS; LYMPHOMA; MALE; METOPROLOL; MIDDLE AGED; PREMEDICATION;

EID: 77958578806     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21840     Document Type: Letter

References (21)

1. Wouters KA, Kremer LC, Miller TL, et al. Protecting against anthracycline-induced myocardial damage: A review of the most promising strategies. Br J Haematol 2005; 131: 561-578.
2. Gianni L, Herman EH, Lipshultz SE, et al. Anthracycline cardiotoxicity: From bench to bedside. J Clin Oncol 2008; 26: 3777-3784.
3. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717.
4. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer 2003; 97: 2869-2879.
5. Limat S, Demesmay K, Voillat L, et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 2003; 14: 277-281.
6. Aviles A, Arevila N, Diaz Maqueo JC, et al. Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults. Leuk Lymphoma 1993; 11: 275-279.
7. Towns K, Bedard PL, Verma S. Matters of the heart: Cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer. Curr Oncol 2008; 15: S16-S29.
8. Bird BR, Swain SM. Cardiac toxicity in breast cancer survivors: Review of potential cardiac problems. Clin Cancer Res 2008; 14: 14-24.
9. van Dalen EC, van der Pal HJ, Caron HN, Kremer LC, et al. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev 2006; CD005008.
10. Gabizon AA. Liposomal anthracyclines. Hematol Oncol Clin North Am 1994; 8: 431-450.
11. Jensen BV, Nielsen SL, Skovsgaard T. Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy. Lancet 1996; 347: 297-299.
12. Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002; 20: 4517-4522.
13. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114: 2474-2481.
14. Noori A, Lindenfeld J, Wolfel E, et al. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail 2000; 6: 115-119.
15. Kalay N, Basar E, Ozdogru I, et al. Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48: 2258-2262.
16. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol 1997; 80: 26L-40L.
17. McDonagh TA, Morrison CE, Lawrence A, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997; 350: 829-833.
18. Davies M, Hobbs F, Davis R, et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the echocardiographic heart of England screening study: A population based study. Lancet 2001; 358: 439-444.
19. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: A prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 2002; 13: 699-709.
20. Cleland J. Diagnosis of heart failure. Heart 1998; 79: S10-S16.
21. Galderisi M, Marra F, Esposito R, et al. Cancer therapy and cardiotoxicity: The need of serial Doppler echocardiography. Cardiovasc Ultrasound 2007; 5: 4.